Biotech Catalysts This Week: 12 Trial Completions, 9 Earnings Reports and 10 New Financings (Nov 1-8, 2026)

· 8 min read

Here’s what’s on the biotech calendar for November 1 to November 8: no FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 9 earnings reports and 10 new financing filings. Last week: 2 timelines pushed back, 1 FDA decision, 8 new timelines announced and 12 key SEC filings.

At a glance: this week no FDA decision dates, 12 Phase 2 or 3 trials reaching primary completion, 9 earnings reports and 10 new financing filings. Last week: 2 timelines pushed back, 1 FDA decision, 8 new timelines announced and 12 key SEC filings.

🔄 What Changed Last Week

Timelines pushed back or discontinued, in the companies’ own words:

  • EXEL pushed back STELLAR-304 from Mid-2026 to first quarter of 2027. Before (2026-01-12): “Topline Results for STELLAR-304 Anticipated Mid-2026.” Now (2026-10-29): “Zanzalintinib GU Highlights Topline Results for Phase 3 STELLAR-304 Pivotal Trial Expected in First Quarter of 2027.” SEC filing
  • ZURA pushed back TibuSURE from third quarter of 2026 to first half of 2027. Before (2025-11-13): “Topline data are expected in the third quarter of 2026. · TibuSURE (SSc): The Phase 2 clinical trial in adults with SSc continued to advance during the quarter.” Now (2026-10-27): “We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first…” SEC filing

All pushed-back and discontinued milestones →

New timelines announced in press releases:

  • MBRX, namycin: in the first quarter of 2027. “The Company remains on track to report comprehensive Part A data in the first quarter of 2027.” SEC filing
  • REGN, baloncibart: in the fourth quarter of 2026. “The Company plans to present interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026 and to initiate a Phase 3 study in…” SEC filing
  • LGND, VANTAGE: in the first quarter of 2027. “On August 5, 2026, Mirum Pharmaceuticals announced enrollment was completed in the VANTAGE Phase 2b study of volixibat in cholestatic pruritus due to primary biliary cholangitis…” SEC filing
  • KYMR, KT-621 BREADTH: in late 2027. “Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma, with topline data expected to be reported in late 2027.” SEC filing
  • PHAT, pHalcon-EoE-201: during the fourth quarter 2026. “Phathom expects to report topline results during the fourth quarter 2026 for the 12-week blinded treatment portion of its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in…” SEC filing
  • STOK, EMPEROR: in the third quarter of 2027. “Enrollment of 162 patients in the primary analysis population (the United States, United Kingdom and Japan) was completed in June 2026, and a data readout from these patients is…” SEC filing
  • ALNY, ALN-6400: in February 2027. “The Company now expects to announce clinical data from the Phase 2 trial of ALN-6400 in patients with hereditary hemorrhagic telangiectasia (HHT), as well as from the Phase 1…” SEC filing
  • BBIO, FORTIFY: late 2027/early 2028. “The MAA will be based on the final analysis of the Phase 3 FORTIFY study at Month 36, with topline results expected late 2027/early 2028.” SEC filing

FDA decisions:

  • INO VOCERYQ: approved (2026-10-30)

Trial status changes on ClinicalTrials.gov:

  • GILD: Phase 2 trial marked completed (2026-10-27). A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Partici Registry

📄 Key SEC Filings Last Week

Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:

  • RADX, 2026-10-30 (clinical trial): Radiopharm reported Q1 business updates including a successful End-of-Phase 2 FDA meeting for RAD101 ahead of a Phase 3 trial starting 1Q27, positive Phase 1 imaging data for RAD301, and completion of a A$12.5 million institutional offer plus a A$3 million Share Purchase Plan. SEC filing
  • MBRX, 2026-10-30 (clinical trial): Moleculin completed dosing in Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin with cytarabine in relapsed or refractory AML. Comprehensive Part A data remain on track for Q1 2027, covering 90 patients. SEC filing
  • ABOS, 2026-10-30 (clinical trial): Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug did not meet its primary endpoint on the iADRS at 18 months at either dose; the company will cease development and explore strategic options and cash conservation. SEC filing
  • RZLT, 2026-10-29 (clinical trial): Rezolute furnished an investor presentation on its website as Exhibit 99.1. It reports $108 million in cash with runway through Q1 2028, and topline data for congenital hyperinsulinism is expected December 2026. The sunRIZE primary endpoint was not met due to confounding placebo effects. SEC filing
  • KYMR, 2026-10-29 (clinical trial): Reported Q3 2026 results with $1.6 billion in cash as of September 30, 2026 and runway into 2029. Announced positive KT-579 Phase 1 healthy volunteer data showing ≥90% median IRF5 degradation in blood and no serious adverse events. KT-621 BROADEN2 AD topline data expected by year-end 2026. SEC filing
  • ATHE, 2026-10-30 (regulatory): Alterity reported A$41.3 million cash at 30 September 2026 after about A$5.5 million from ATHO option exercises and a A$3.98 million R&D tax refund. FDA End-of-Phase 2 minutes confirmed a Phase 3 design for ATH434 in MSA, with about 200 patients randomized 1:1 for 12 months. SEC filing
  • RFL, 2026-10-29 (regulatory): Reported a fiscal 2026 net loss of $29.6 million, or $0.58 per share, and cash of $22.1 million. Cyclo Therapeutics submitted an NDA to the FDA for remibetadex in Niemann-Pick Disease Type C, after the Phase 3 study missed its overall primary endpoint (p=0.19). SEC filing
  • HCM, 2026-10-29 (regulatory): Sovleplenib, an oral Syk inhibitor, was granted FDA Orphan Drug Designation for primary immune thrombocytopenia, which carries 7 years of US market exclusivity if approved. NDAs for primary ITP and warm antibody autoimmune hemolytic anemia are under NMPA review in China. SEC filing
  • PTHS, 2026-10-30 (deal): Pelthos agreed to merge with Castle Creek Biosciences in a two-step deal. Castle Creek holders get 5,200,000 Pelthos shares at closing, plus contingent shares, up to $300 million in milestones and a share of any priority review voucher tied to D-Fi. Closing is expected by end of Q1 2027. SEC filing
  • PLUR, 2026-10-30 (deal): Pluri entered a partnership agreement with ZEO ScientifiX granting ZEO an exclusive U.S. license to manufacture and commercialize its regenerative medicine products, excluding aesthetics, skin care, cosmetic and veterinary uses. SEC filing
  • CMMB, 2026-10-30 (deal): Chemomab and Scipher Medicine agreed to a merger, with Chemomab’s Israeli parent domesticating to Delaware first. Chemomab holders expected to own about 32% of the combined company. Scipher’s 2026 notes convert into shares and 2025 notes are cancelled. SEC filing
  • NMRA, 2026-10-30 (listing): Received Nasdaq notice on October 26, 2026 for noncompliance with the $1.00 minimum bid price requirement. The company has until April 26, 2027 to regain compliance, requiring a closing bid of at least $1.00 for ten consecutive business days, and may consider a reverse stock split. SEC filing

🧪 Phase 2 and 3 Trials Reaching Primary Completion

Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.

  • SRRK, 2026-11-01 (Phase 3): Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab Registry
  • VRCA, 2026-11-01 (Phase 3): Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) Registry
  • NAMS, 2026-11-01 (Phase 3): Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease Registry
  • IMUX, 2026-11-01 (Phase 3): Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Registry
  • IMUX, 2026-11-01 (Phase 3): Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Registry
  • HRMY, 2026-11-01 (Phase 3): An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Registry
  • CGON, 2026-11-01 (Phase 3): A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Registry
  • DRUG, 2026-11-01 (Phase 3): Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt Registry
  • BMY, 2026-11-01 (Phase 3): A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Registry
  • BMY, 2026-11-02 (Phase 3): A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) Registry
  • NVS, 2026-11-03 (Phase 3): 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 – <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up Registry
  • ALKS, 2026-11-01 (Phase 2): A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia Registry

📊 Earnings This Week

  • AXSM: 2026-11-02 (est. EPS -0.2976)
  • CMPS: 2026-11-02 (est. EPS -0.4978)
  • CORT: 2026-11-02 (est. EPS 0.6528)
  • IBRX: 2026-11-02 (est. EPS -0.0740)
  • ARVN: 2026-11-03 (est. EPS -0.7467)
  • ACHV: 2026-11-04 (est. EPS -0.1682)
  • EWTX: 2026-11-04 (est. EPS 1.8156)
  • GLUE: 2026-11-04 (est. EPS -0.4073)
  • MAIA: 2026-11-05 (est. EPS -0.1224)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • TECX: Phase 2 primary completion in 23 days, score 57/100
  • SKYE: Phase 2 primary completion in 19 days, score 57/100
  • BBIO: FDA decision (NDA) in 26 days, score 56/100

💸 Dilution Watch: New Financing Filings

  • VOR: ATM program up to $150M (424B5, 2026-10-30) EDGAR
  • RGEN: private placement (8-K, 2026-10-30) EDGAR
  • RAPP: convertible notes (424B5, 2026-10-30) EDGAR
  • RAPP: private placement (8-K, 2026-10-30) EDGAR
  • PTHS: private placement (8-K, 2026-10-30) EDGAR
  • PLUR: private placement (8-K, 2026-10-30) EDGAR
  • APVO: ATM program up to $50M (424B5, 2026-10-30) EDGAR
  • PROK: shelf with ATM program up to $200M (S-3, 2026-10-29) EDGAR
  • LXEO: shelf registration up to $300M (S-3, 2026-10-29) EDGAR
  • INMB: registered direct offering (424B5, 2026-10-29) EDGAR

Full Dilution Watch table →

📉 Downside Radar: Trading Far Below a Recent Offering

Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:

  • MDCX: $1.88, 77% below $8.15, its close on the day of its Sep 11 private placement
  • JAGX: $1.62, 73% below $6.02, its close on the day of its Sep 28 private placement
  • BSEM: $1.12, 64% below $3.09, its close on the day of its Sep 30 private placement
  • GRML: $4.58, 61% below $11.85, its close on the day of its Sep 28 registered direct offering
  • BKHA: $4.72, 61% below $12.19, its close on the day of its Sep 24 private placement
  • SBFM: $2.93, 57% below $6.76, its close on the day of its Oct 9 registered direct offering (new this week)
  • HCWB: $1.10, 45% below $1.99, its close on the day of its Sep 24 private placement
  • BIAF: $2.91, 38% below $4.72, its close on the day of its Oct 9 private placement

Full Downside Radar and how it was tested →

📉 Downside Radar: Financing Pressure

12 months of cash or less, an ATM program, shelf or S-1 on file and no offering in 90 days. Of biotech stocks in this setup, 41% sold new shares within three months (10% of comparable stocks) and 69% were lower 60 trading days later, median -17%; with 6 months of cash or less, 51% and 73%. Shortest cash first:

  • MTNB: about 1.3 months of cash (Jun 30 balance sheet), shelf registration filed Jun 16
  • CUE: about 2.6 months of cash (Jun 30 balance sheet), shelf registration filed Mar 16
  • NNVC: about 4.1 months of cash (Jun 30 balance sheet), ATM program filed Oct 21 (new this week)
  • BIVI: about 4.7 months of cash (Jun 30 balance sheet), ATM program filed Sep 14
  • BHVN: about 5.0 months of cash (Sep 30 balance sheet), shelf registration filed May 4
  • SDEV: about 5.4 months of cash (Jun 30 balance sheet), ATM program filed Jan 20 (new this week)
  • PRME: about 6.8 months of cash (Jun 30 balance sheet), shelf registration filed Nov 7
  • ELTX: about 7.1 months of cash (Jun 30 balance sheet), ATM program filed Mar 16

The financing-pressure list and how it was tested →

📈 Last Week’s Biggest Gainers

  • ADIL +36.12% (volume 1.4x average)
  • BHC +28.76% (volume 9.2x average)
  • BYSI +24.26% (volume 0.3x average)
  • KNSA +22.23% (volume 3.8x average)
  • PDSB +22.07% (volume 0.4x average)

Earlier weekly catalyst recaps →

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.